Advances in Precision Medicine of Oncology Radiotherapy
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: 15 December 2026 | Viewed by 1456
Special Issue Editors
Interests: radiotherapy; oncology; drug treatment; immunotherapy
Special Issue Information
Dear Colleagues,
Radiation is one of the most effective therapies to cure cancer. It is estimated that approximately 60% of cancer pa-tients will receive radiotherapy for curative, adjuvant, neo-adjuvant, or palliative purposes during the course of their disease. Advancements in anti-cancer treatments have resulted in significant progress in the field of oncology, thereby enhancing treatment outcomes. This progress has yielded substantial benefits, encompassing enhanced disease management, prolonged survival rates, and the improvement in patients' quality of life.
The aforementioned benefits were observed across both patients with localised disease and those with advanced disease, including those who experienced a relapse following initial treatment regimens. Special attention is now directed towards patients identified as oligo-metastatic, who are considered part of the category of stage IV patients and were previously deemed incurable. These patients have shown benefits from integrated treatment regimens that incorporate new-generation drugs (biotherapeutics, immunotherapeutics) in conjunction with local treatments such as radiotherapy. This combination has also resulted in a substantial improvement in overall survival rates.
A number of studies are ongoing, investigating new radiation techniques and alternative schedules for delivering doses, with the aim of improving the therapeutic window. Investigations into the radiobiological principles of radiotherapy have resulted in a more comprehensive understanding of its mechanisms. Furthermore, the identification of possible radiation schedules adapted to treat both different tumour histotypes and tumour subvolumes is advancing. Another aspect that should be considered is the potential impact of low-dose radiation on the immune system. It has been established that doses of up to 3 Gy can stimulate immune cell activation, thereby enhancing the efficacy of immunotherapeutic interventions.
Moreover, omics approaches have great potential in radiation research. They can provide new ways to diagnose and study disease progression or relapse.
This Special Issue will provide a comprehensive overview of the effects of radiotherapy combined with new systemic treatments, including target agents and immunotherapy. In addition, it will examine the feasibility of using modified dose fractionation schemes to kill cancer cells and boost the immune system. Possible topics for discussion in this Special Issue include predictive biomarkers, quality of life during cancer treatment, technical advances in radiotherapy, and new diagnostic methodologies that could be used to personalise therapies and predict outcomes.
We welcome the latest research articles and comprehensive reviews about all aspects of oncology radiotherapy.
Dr. Giuseppe Iatí
Dr. Silvana Parisi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel radiotherapy approaches
- novel drugs
- novel diagnostic approaches
- immunomodulation
- omics
- biomarkers
- metabolic alterations
- personalised medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
